Bejon P

Detecting Malaria Hotspots: A Comparison of Rapid Diagnostic Test, Microscopy, and Polymerase Chain Reaction.Mogeni, P. Williams, T. N. Omedo, I. Kimani, D. Ngoi, J. M. Mwacharo, J. Morter, R. Nyundo, C. Wambua, J. Nyangweso, G. Kapulu, M. Fegan, G. Bejon, P.
J Infect Dis, (2017). 216:1091-1098

Proteomic analysis of extracellular vesicles from a Plasmodium falciparum Kenyan clinical isolate defines a core parasite secretome.Abdi, A. Yu, L. Goulding, D. Rono, M. K. Bejon, P. Choudhary, J. Rayner, J.
Wellcome Open Res, (2017). 2:50

Geographic-genetic analysis of Plasmodium falciparum parasite populations from surveys of primary school children in Western Kenya.Omedo, I. Mogeni, P. Rockett, K. Kamau, A. Hubbart, C. Jeffreys, A. Ochola-Oyier, L. I. de Villiers, E. P. Gitonga, C. W. Noor, A. M. Snow, R. W. Kwiatkowski, D. Bejon, P.
Wellcome Open Res, (2017). 2:29

Plasmodium falciparum malaria parasite var gene expression is modified by host antibodies: longitudinal evidence from controlled infections of Kenyan adults with varying natural exposure.Abdi, A. I. Hodgson, S. H. Muthui, M. K. Kivisi, C. A. Kamuyu, G. Kimani, D. Hoffman, S. L. Juma, E. Ogutu, B. Draper, S. J. Osier, F. Bejon, P. Marsh, K. Bull, P. C.
BMC Infect Dis, (2017). 17:585

Effect of transmission intensity on hotspots and micro-epidemiology of malaria in sub-Saharan Africa.Mogeni, P. Omedo, I. Nyundo, C. Kamau, A. Noor, A. Bejon, P. Hotspot Group, Authors
BMC Med, (2017). 15:121

Micro-epidemiological structuring of Plasmodium falciparum parasite populations in regions with varying transmission intensities in Africa.Omedo, I. Mogeni, P. Bousema, T. Rockett, K. Amambua-Ngwa, A. Oyier, I. C. Stevenson J Y. Baidjoe A de Villiers, E. P. Fegan, G. Ross, A. Hubbart, C. Jeffreys, A. N. Williams T Kwiatkowski, D. Bejon, P.
Wellcome Open Res, (2017). 2:10

Efficacy of text-message reminders on paediatric malaria treatment adherence and their post-treatment return to health facilities in Kenya: a randomized controlled trial.Talisuna, A. O. Oburu, A. Githinji, S. Malinga, J. Amboko, B. Bejon, P. Jones, C. Snow, R. W. Zurovac, D.
Malar J, (2017). 16:46

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.Mensah, V. A. Gueye, A. Ndiaye, M. Edwards, N. J. Wright, D. Anagnostou, N. A. Syll, M. Ndaw, A. Abiola, A. Bliss, C. Gomis, J. F. Petersen, I. Ogwang, C. Dieye, T. Viebig, N. K. Lawrie, A. M. Roberts, R. Nicosia, A. Faye, B. Gaye, O. Leroy, O. Imoukhuede, E. B. Ewer, K. J. Bejon, P. Hill, A. V. Cisse, B. Mvvc group
PLoS One, (2016). 11:e0167951

The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum - an epidemiological "natural experiment".Bediako, Y. Ngoi, J. M. Nyangweso, G. Wambua, J. Opiyo, M. Nduati, E. W. Bejon, P. Marsh, K. Ndungu, F. M.
BMC Med, (2016). 14:143

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.Olotu, A. Fegan, G. Wambua, J. Nyangweso, G. Leach, A. Lievens, M. Kaslow, D. C. Njuguna, P. Marsh, K. Bejon, P.
N Engl J Med, (2016). 374:2519-29

Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study.Mogeni, P. Williams, T. N. Fegan, G. Nyundo, C. Bauni, E. Mwai, K. Omedo, I. Njuguna, P. Newton, C. R. Osier, F. Berkley, J. A. Hammitt, L. L. Lowe, B. Mwambingu, G. Awuondo, K. Mturi, N. Peshu, N. Snow, R. W. Noor, A. Marsh, K. Bejon, P.
PLoS Med, (2016). 13:e1002047

Comparison of allele frequencies of Plasmodium falciparum merozoite antigens in malaria infections sampled in different years in a Kenyan population.Ochola-Oyier, L. I. Okombo, J. Wagatua, N. Ochieng, J. Tetteh, K. K. Fegan, G. Bejon, P. Marsh, K.
Malar J, (2016). 15:261

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.Afolabi, M. O. Tiono, A. B. Adetifa, U. J. Yaro, J. B. Drammeh, A. Nebie, I. Bliss, C. Hodgson, S. H. Anagnostou, N. A. Sanou, G. S. Jagne, Y. J. Ouedraogo, O. Tamara, C. Ouedraogo, N. Ouedraogo, M. Njie-Jobe, J. Diarra, A. Duncan, C. J. Cortese, R. Nicosia, A. Roberts, R. Viebig, N. K. Leroy, O. Lawrie, A. M. Flanagan, K. L. Kampman, B. Bejon, P. Imoukhuede, E. B. Ewer, K. J. Hill, A. V. Bojang, K. Sirima, S. B.
Mol Ther, (2016). 24:1470-7

Malaria hotspots defined by clinical malaria, asymptomatic carriage, PCR and vector numbers in a low transmission area on the Kenyan Coast.Kangoye, D. T. Noor, A. Midega, J. Mwongeli, J. Mkabili, D. Mogeni, P. Kerubo, C. Akoo, P. Mwangangi, J. Drakeley, C. Marsh, K. Bejon, P. Njuguna, P.
Malar J, (2016). 15:213

A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens.Tan, J. Pieper, K. Piccoli, L. Abdi, A. Perez, M. F. Geiger, R. Tully, C. M. Jarrossay, D. Maina Ndungu, F. Wambua, J. Bejon, P. Fregni, C. S. Fernandez-Rodriguez, B. Barbieri, S. Bianchi, S. Marsh, K. Thathy, V. Corti, D. Sallusto, F. Bull, P. Lanzavecchia, A.
Nature, (2016). 529:105-109

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.Kangoye, D. T. Mensah, V. A. Murungi, L. M. Nkumama, I. Nebie, I. Marsh, K. Cisse, B. Bejon, P. Osier, F. H. Sirima, S. B. Mvvc Infant Immunology Study Group
Vaccine, (2016). 34:160-6

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.Agnandji, S. T. Huttner, A. Zinser, M. E. Njuguna, P. Dahlke, C. Fernandes, J. F. Yerly, S. Dayer, J. A. Kraehling, V. Kasonta, R. Adegnika, A. A. Altfeld, M. Auderset, F. Bache, E. B. Biedenkopf, N. Borregaard, S. Brosnahan, J. S. Burrow, R. Combescure, C. Desmeules, J. Eickmann, M. Fehling, S. K. Finckh, A. Goncalves, A. R. Grobusch, M. P. Hooper, J. Jambrecina, A. Kabwende, A. L. Kaya, G. Kimani, D. Lell, B. Lemaitre, B. Lohse, A. W. Massinga-Loembe, M. Matthey, A. Mordmuller, B. Nolting, A. Ogwang, C. Ramharter, M. Schmidt-Chanasit, J. Schmiedel, S. Silvera, P. Stahl, F. R. Staines, H. M. Strecker, T. Stubbe, H. C. Tsofa, B. Zaki, S. Fast, P. Moorthy, V. Kaiser, L. Krishna, S. Becker, S. Kieny, M. P. Bejon, P. Kremsner, P. G. Addo, M. M. Siegrist, C. A.
N Engl J Med, (2016). 374:1647-60

Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial.Li, H. K. Scarborough, M. Zambellas, R. Cooper, C. Rombach, I. Walker, A. S. Lipsky, B. A. Briggs, A. Seaton, A. Atkins, B. Woodhouse, A. Berendt, A. Byren, I. Angus, B. Pandit, H. Stubbs, D. McNally, M. Thwaites, G. Bejon, P.
Trials, (2015). 16:583

Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya.Atkinson, S. H. Uyoga, S. M. Armitage, A. E. Khandwala, S. Mugyenyi, C. K. Bejon, P. Marsh, K. Beeson, J. G. Prentice, A. M. Drakesmith, H. Williams, T. N.
EBioMedicine, (2015). 2:1478-86

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.Neafsey, D. E. Juraska, M. Bedford, T. Benkeser, D. Valim, C. Griggs, A. Lievens, M. Abdulla, S. Adjei, S. Agbenyega, T. Agnandji, S. T. Aide, P. Anderson, S. Ansong, D. Aponte, J. J. Asante, K. P. Bejon, P. Birkett, A. J. Bruls, M. Connolly, K. M. D'Alessandro, U. Dobano, C. Gesase, S. Greenwood, B. Grimsby, J. Tinto, H. Hamel, M. J. Hoffman, I. Kamthunzi, P. Kariuki, S. Kremsner, P. G. Leach, A. Lell, B. Lennon, N. J. Lusingu, J. Marsh, K. Martinson, F. Molel, J. T. Moss, E. L. Njuguna, P. Ockenhouse, C. F. Ogutu, B. R. Otieno, W. Otieno, L. Otieno, K. Owusu-Agyei, S. Park, D. J. Pelle, K. Robbins, D. Russ, C. Ryan, E. M. Sacarlal, J. Sogoloff, B. Sorgho, H. Tanner, M. Theander, T. Valea, I. Volkman, S. K. Yu, Q. Lapierre, D. Birren, B. W. Gilbert, P. B. Wirth, D. F.
N Engl J Med, (2015). 373:2025-2037